[go: up one dir, main page]

WO2009124553A3 - Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia - Google Patents

Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia Download PDF

Info

Publication number
WO2009124553A3
WO2009124553A3 PCT/DK2009/000092 DK2009000092W WO2009124553A3 WO 2009124553 A3 WO2009124553 A3 WO 2009124553A3 DK 2009000092 W DK2009000092 W DK 2009000092W WO 2009124553 A3 WO2009124553 A3 WO 2009124553A3
Authority
WO
WIPO (PCT)
Prior art keywords
ischemia
treatment
cannabinoid receptor
receptor agonists
inducing drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2009/000092
Other languages
French (fr)
Other versions
WO2009124553A2 (en
Inventor
Uno Jakob Weber
Jacob Gotfredsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEUROKEY AS
Original Assignee
NEUROKEY AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NEUROKEY AS filed Critical NEUROKEY AS
Publication of WO2009124553A2 publication Critical patent/WO2009124553A2/en
Publication of WO2009124553A3 publication Critical patent/WO2009124553A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to the use of a cannabinoid receptor agonist for use in induction of hypothermia in a human being for the prophylaxis and treatment of ischemia.
PCT/DK2009/000092 2008-04-09 2009-04-08 Use of hypothermia inducing drugs Ceased WO2009124553A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200800515 2008-04-09
DKPA200800515 2008-04-09
DKPA200801141 2008-08-21
DKPA200801141 2008-08-21

Publications (2)

Publication Number Publication Date
WO2009124553A2 WO2009124553A2 (en) 2009-10-15
WO2009124553A3 true WO2009124553A3 (en) 2009-12-03

Family

ID=41130582

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2009/000092 Ceased WO2009124553A2 (en) 2008-04-09 2009-04-08 Use of hypothermia inducing drugs

Country Status (1)

Country Link
WO (1) WO2009124553A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969347B2 (en) 2008-06-03 2015-03-03 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US9359379B2 (en) 2012-10-02 2016-06-07 Intermune, Inc. Anti-fibrotic pyridinones

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200808773A (en) 2006-06-23 2008-02-16 Abbott Lab Cyclopropyl amine derivatives
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
US8608696B1 (en) 2009-02-24 2013-12-17 North Carolina State University Rapid fluid cooling devices and methods for cooling fluids
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
WO2012037258A1 (en) 2010-09-16 2012-03-22 Abbott Laboratories Processes for preparing 1,2-substituted cyclopropyl derivatives
JP6525437B2 (en) 2014-04-02 2019-06-05 インターミューン， インコーポレイテッド Antifibrotic pyridinone

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837228A (en) * 1979-05-31 1989-06-06 The University Of Mississippi Antiinflammatory and antimicrobial compounds and compositions
WO2001024645A1 (en) * 1999-10-07 2001-04-12 Societe Des Produits Nestle S.A. Nutritional composition
WO2004004702A2 (en) * 2002-07-09 2004-01-15 The Scripps Research Institute Method to inhibit ischemia and reperfusion injury
US20040229850A1 (en) * 2003-05-12 2004-11-18 Moore Bob M. Method and kit for regulation of microvascular tone
WO2004105699A2 (en) * 2003-05-28 2004-12-09 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
US20070203209A1 (en) * 2005-08-18 2007-08-30 Wilmin Bartolini Useful indole compounds
WO2007140786A1 (en) * 2006-06-08 2007-12-13 Neurokey A/S Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia
WO2008040360A2 (en) * 2006-10-04 2008-04-10 Neurokey A/S Use of hypothermia inducing drugs to treat ischemia
WO2008116816A1 (en) * 2007-03-26 2008-10-02 Glaxo Group Limited Combination of cb2 ligand and paracetamol
WO2009071095A2 (en) * 2007-12-05 2009-06-11 Neurokey A/S Prevention of hyperthermia subsequent to hypothermia treatment of ischemia

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837228A (en) * 1979-05-31 1989-06-06 The University Of Mississippi Antiinflammatory and antimicrobial compounds and compositions
WO2001024645A1 (en) * 1999-10-07 2001-04-12 Societe Des Produits Nestle S.A. Nutritional composition
WO2004004702A2 (en) * 2002-07-09 2004-01-15 The Scripps Research Institute Method to inhibit ischemia and reperfusion injury
US20040229850A1 (en) * 2003-05-12 2004-11-18 Moore Bob M. Method and kit for regulation of microvascular tone
WO2004105699A2 (en) * 2003-05-28 2004-12-09 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
US20070203209A1 (en) * 2005-08-18 2007-08-30 Wilmin Bartolini Useful indole compounds
WO2007140786A1 (en) * 2006-06-08 2007-12-13 Neurokey A/S Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia
WO2008040360A2 (en) * 2006-10-04 2008-04-10 Neurokey A/S Use of hypothermia inducing drugs to treat ischemia
WO2008116816A1 (en) * 2007-03-26 2008-10-02 Glaxo Group Limited Combination of cb2 ligand and paracetamol
WO2009071095A2 (en) * 2007-12-05 2009-06-11 Neurokey A/S Prevention of hyperthermia subsequent to hypothermia treatment of ischemia

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AHN ET AL: "Blockade of central cyclooxygenase (COX) pathways enhances the cannabinoid-induced antinociceptive effects on inflammatory temporomandibular joint (TMJ) nociception", PAIN, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 132, no. 1-2, 3 October 2007 (2007-10-03), pages 23 - 32, XP022283606, ISSN: 0304-3959 *
GUINDON J ET AL: "Synergistic antinociceptive effects of anandamide, an endocannabinoid, and nonsteroidal anti-inflammatory drugs in peripheral tissue: A role for endogenous fatty-acid ethanolamides?", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER BV, NL, vol. 550, no. 1-3, 21 November 2006 (2006-11-21), pages 68 - 77, XP025170094, ISSN: 0014-2999, [retrieved on 20061121] *
LEKER RONEN R ET AL: "Drug-induced hypothermia reduces ischemic damage: effects of the cannabinoid HU-210", STROKE, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 34, no. 8, 1 August 2003 (2003-08-01), pages 2000 - 2006, XP002451424, ISSN: 0039-2499 *
SLIVA JIRI ET AL: "Analgesic efficacy of CP 55940 in combination with diclofenac in rodents", ACTA PHARMACOLOGICA SINICA, vol. 27, no. Suppl. 1, July 2006 (2006-07-01), & 15TH WORLD CONGRESS OF PHARMACOLOGY; BEIJING, PEOPLES R CHINA; JULY 02 07, 2006, pages 113, XP009123932, ISSN: 1671-4083 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969347B2 (en) 2008-06-03 2015-03-03 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US9359379B2 (en) 2012-10-02 2016-06-07 Intermune, Inc. Anti-fibrotic pyridinones

Also Published As

Publication number Publication date
WO2009124553A2 (en) 2009-10-15

Similar Documents

Publication Publication Date Title
IL195560A0 (en) Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia
WO2009124553A3 (en) Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia
IL262838A (en) Guanylate cyclase agonists for use in the treatment of hypercholesterolemia
IL205704A (en) Use of alpha adrenergic receptor agonists in the preparation of medicaments for treating purpura
ZA201105323B (en) Agonists and antagonists of the sip5 receptor,and methods of uses thereof
IL216582A0 (en) Composition for use in decreasing the transmission of human pathogens, devices comprising the same and uses thereof
EP2306994A4 (en) S1p1 receptor agonists and use thereof
IL213168A0 (en) 1,2,4-oxadiazole derivatives and their therapeutic use
IL210514A0 (en) Pyridino-pyridinone derivatives, preparation thereof, and therapeutic use thereof
IL197553A0 (en) Use of hypothermia inducing drugs
WO2011156479A3 (en) Trkb agonists and methods of use
IL209840A0 (en) Azacarboline derivatives, preparation thereof, and therapeutic use thereof as kinase inhibitors
IL216967B (en) 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives and use thereof for the treatment of diseases
WO2009114740A9 (en) Use of gabaa receptor antagonists for the treatment of excessive sleepiness and disorders associated with excessive sleepiness
IL201416A0 (en) Triazolopyridine carboxamide derivatives, preparation thereof and theraputic use thereof
ZA201002113B (en) Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine h3 receptor modulators
IL219888A0 (en) Pyridine-pyridinone derivatives, preparation and therapeutic use thereof
MX2011010782A (en) 5-ht4 receptor agonist compounds for treatment of cognitive disorders.
IL226370A (en) Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes
IL207629A0 (en) Novel 3-aminoalkyl-1,3-dihydro-2h-indol-2-one derivatives, preparation thereof and therapeutic use thereof
IL217300A0 (en) Pyrazole derivatives' prepartion thereof, and therapeutic use thereof
ZA201302340B (en) Adenosine a1 agonists for the treatment of glaucoma and ocular hypertension
EP2209377B8 (en) Use of vitamin d receptor agonists and precursors to treat fibrosis
IL237332A0 (en) Pyrazole carboxamide derivatives as taar modulators for use in the treatment of several disorders, such as depression, diabetes and parkinson's disease
SI2421864T1 (en) 1-pyrazološ4,3-cćisoquinoline derivatives, preparation thereof and therapeutic use thereof

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 07/02/2011)

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09730274

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 09730274

Country of ref document: EP

Kind code of ref document: A2